BI Asset Management Fondsmaeglerselskab A S Invests $6.01 Million in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 272,634 shares of the company's stock, valued at approximately $6,009,000.

Several other institutional investors and hedge funds have also modified their holdings of TEVA. Oarsman Capital Inc. acquired a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at $29,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $50,000. Ameliora Wealth Management Ltd. bought a new stake in Teva Pharmaceutical Industries in the fourth quarter worth $66,000. IFP Advisors Inc increased its position in Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after buying an additional 1,960 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its position in shares of Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock worth $96,000 after buying an additional 949 shares during the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock traded up $0.42 during midday trading on Thursday, reaching $14.71. 8,358,482 shares of the company's stock were exchanged, compared to its average volume of 9,938,242. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The firm has a market cap of $16.68 billion, a price-to-earnings ratio of -10.14, a P/E/G ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 52 week low of $12.47 and a 52 week high of $22.80. The stock's 50-day simple moving average is $15.30 and its 200 day simple moving average is $17.60.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TEVA has been the subject of a number of research analyst reports. Bank of America cut their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. UBS Group lowered their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Barclays lowered their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. Finally, StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.